Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs ENVARSUS XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Mild to moderate pain,Fever
Prophylaxis of organ rejection in kidney transplant patients,Prophylaxis of organ rejection in liver transplant patients
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic via CYP3A4 and CYP3A5; also metabolized by intestinal CYP3A4.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 99% bound to erythrocytes and plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
0.9-1.4 L/kg in renal transplant patients; large volume indicates extensive tissue distribution, particularly to red blood cells.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral bioavailability is approximately 15-25% with the extended-release formulation; reduced by high-fat meal, so should be taken consistently on an empty stomach.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific GFR-based dose adjustment; however, due to nephrotoxicity, monitor renal function closely and reduce dose if renal impairment occurs. For patients with severe renal impairment (Cr Cl <30 m L/min), consider alternative immunosuppression.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
In patients with mild to moderate hepatic impairment (Child-Pugh A or B), reduce dose by 25%. For severe hepatic impairment (Child-Pugh C), reduce dose by 50% and monitor trough levels closely.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For pediatric kidney transplant recipients: 0.2 mg/kg/day orally once daily, with morning meal. Adjust to target trough concentrations. Safety and efficacy not established for other indications in pediatrics.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment; however, elderly patients may have increased susceptibility to nephrotoxicity and neurotoxicity. Use lowest effective dose, monitor renal function, and adjust based on trough levels.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Increased susceptibility to infection and possible development of malignancy (e.g., lymphoma, skin cancer).
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Nephrotoxicity, neurotoxicity, hypertension, hyperkalemia, post-transplant diabetes mellitus, monitoring of blood concentrations required.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to tacrolimus or any component of the formulation.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Grapefruit and grapefruit juice increase tacrolimus exposure and must be avoided. High-fat meals may decrease absorption; consistency of food intake relative to dosing is recommended. Alcohol should be limited due to potential additive hepatotoxicity.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on animal studies; human data are limited but suggest a possible small increase. During the second and third trimesters, risks include intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Advise women of childbearing potential to use effective contraception.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Tacrolimus is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5 (range 0.12–0.75). Infant exposure is estimated to be <1% of the maternal weight-adjusted dose, which is considered low. However, due to potential for immunosuppression and adverse effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for signs of immunosuppression.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Pregnancy induces pharmacokinetic changes including increased volume of distribution, altered protein binding, and enhanced clearance of tacrolimus. Frequent monitoring of trough concentrations is essential to maintain therapeutic levels (target 5–10 ng/m L). Dose adjustments (increases of 20–50% or more) are often required, especially during the second and third trimesters. Postpartum, doses should be reduced to pre-pregnancy levels within 1–2 weeks.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
ENVARSUS XR is an extended-release formulation of tacrolimus; conversion from immediate-release tacrolimus requires close therapeutic drug monitoring due to altered pharmacokinetics. Administer consistently with or without food to minimize variability. Avoid grapefruit products. Monitor renal function, blood pressure, electrolytes, glucose, and trough tacrolimus levels. CYP3A4/5 inducers/inhibitors significantly affect tacrolimus exposure; adjust dose accordingly. Do not crush, chew, or split tablets.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take exactly as prescribed, at the same time each day, with or without food but consistently.,Swallow whole; do not crush, chew, or break the tablet.,Avoid grapefruit and grapefruit juice.,Do not stop or change dose without consulting your doctor.,Report signs of infection (fever, sore throat), tremor, headache, changes in urination, or unusual bleeding.,Avoid live vaccines and limit sun exposure due to increased skin cancer risk.,Keep all appointments for blood tests to monitor drug levels and organ function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs ENVARSUS XR, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. ENVARSUS XR is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and ENVARSUS XR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of ENVARSUS XR is: 0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and ENVARSUS XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. ENVARSUS XR is classified as Category C. Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on anima. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.